Spondyloarthritiden einschließlich Psoriasis-Arthritis

Schlüsselwörter

Spondyloarthritis - Psoriasisarthritis - Frühdiagnostik - Komorbidität - Therapie

Keywords

spondyloarthritis - psoriatic arthritis - early diagnosis - co-morbidity - therapy

• Literatur

• 1 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschafte. Leitlinie „Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen“. . Registernummer 060-003. http://www.awmf.org/ leitlinien/detail/ll/060-003.html
• 2 Braun A, Gnann H, Saracbasi E et al. Optimizing the identification of patients with axial spondyloarthritis in primary care – the case for a two-step strategy combining the most relevant clinical items with HLA-B27. Rheumatology (Oxford) 2013; 52: 1418-1424
• 3 de Hooge M, van den Berg R, Navarro-Compán V et al. Magnetic resonance imaging of the sacroiliac joints in the early detection of spondyloarthritis: no added value of gadolinium compared with short tau inversion recovery sequence. Rheumatology (Oxford) 2013; 52: 1220-1224
• 4 Gladman D, Fleischmann R, Coteur G et al. Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of the RAPID-PsA study. Arthritis Care Res (Hoboken) 2014; 66: 1085-1092
• 5 Haroon M, Gallagher P, Heffernan E et al. High prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis is associated with the severity of underlying disease. J Rheumatol 2014; 41: 1357-1365
• 6 Kavanaugh A, Mease PJ, Gomez-Reino JJ et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014; 73: 1020-1026
• 7 Landewé R, Braun J, Deodhar A et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 2014; 73: 39-47
• 8 Mease PJ, Fleischmann R, Deodhar AA et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 2014; 73: 48-55
• 9 Merola JF, Wu S, Han J et al. Psoriasis, psoriatic arthritis and risk of gout in US men and women. Ann Rheum Dis 2014; Mar 20. DOI: 10.1136/annrheumdis-2014-205212.
• 10 Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?. Arthritis Rheum 2005; 52: 1000-1008
• 11 Sieper J, Porter-Brown B, Thompson L et al. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis 2014; 73: 95-100
• 12 Sieper J, van der Heijde D. Nonradiographic axial spondyloarthritis: new definition of an old disease?. Arthritis Rheumatol 2013; 65: 543-551
• 13 van der Heijde D, Sieper J, Maksymowych WP et al. Spinal inflammation in the absence of sacroiliac joint inflammation on MRI in patients with active non-radiographic axial spondyloarthritis. Arthritis Rheumatol 2014; 66: 667-673